Key facts
- It has raised $2.5M; the latest was Early Stage VC ($2.5M) in Mar 2026.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Nobel Prize Life Sciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Nobel Prize Life Sciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nobel Prize Life Sciences
Provider of health technology research focused on AI-driven sub-health prevention and chronic disease management. The company develops cell technology research, medical research programs, experimental development services, health data analysis tools and AI-based health management technologies that serve healthcare institutions and research organizations and enable personalized health monitoring and disease prevention.
- Sector
- Healthcare
- HQ
- Jinan, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Nobel Prize Life Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nobel Prize Life Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nobel Prize Life Sciences in its N-PORT filings yet. We sweep new filings monthly.